Stakeholder Opinions: Ophthalmology - Leading brands under threat

Ophthalmology encompasses some lucrative markets, but the future of leading brands in glaucoma and AMD is under threat, and while established markets like glaucoma and conjunctivitis have many therapeutic options, diabetic retinopathy remains largely untapped. Key opinion leaders agree there is unmet need in terms of drug delivery methods and dose frequency across ophthalmology diseases.

Scope

*Snapshot of ophthalmology diseases based on the worldwide leading causes of blindness

*Review of current treatment options, and epidemiology in eye diseases in each of the seven major markets and selected rest of the world regions

*Analysis of ophthalmology ATC drug classes with assessment of key brand and country dynamics

*Assessment of unmet needs based on key opinion leader interviews and a review of pipeline therapies in leading ophthalmic diseases

Highlights

The future of leading brands Lucentis (ranibizumab) and Xalatan (latanoprost) is at risk. Lucentis dominates AMD with 91% market share but the use of currently off-label Avastin (bevacizumab, Roche) is a threat. Xalatan, the gold standard in glaucoma achieved $1.5 billion in 2008 but the drug faces generic erosion after patent expiry in 2011

Diabetic retinopathy and AMD markets show high growth potential. Both diseases are highly prevalent, with 11.5 million cases of diabetic retinopathy, and 7.5 million in AMD, in the seven major markets in 2010. There are few drug treatments for AMD, while no approved drugs for diabetic retinopathy mean this market is untapped.

Key opinion leaders report high unmet need for reduced dosing regimens of existing therapies and an improvement in drug delivery methods. However, any new formulations of existing drugs will have to compete with cheap generics and need to show significant additional benefits.

Reasons to Purchase

*Validate the market potential of particular ophthalmology indications based on prevalence numbers in each of the seven major markets

*Understand the commercial potential of ophthalmic diseases with Datamonitor’s assessment of market and brand dynamics

*Assess the key unmet needs and possible new approaches in the treatment of eye diseases as noted by opinion leaders

Post a comment